keyword
MENU ▼
Read by QxMD icon Read
search

Seth Baum

keyword
https://www.readbyqxmd.com/read/28639183/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-and-its-inhibitors-a-review-of-physiology-biology-and-clinical-data
#1
REVIEW
Ashwin Durairaj, Alberto Sabates, Jonathan Nieves, Brian Moraes, Seth Baum
Atherosclerotic cardiovascular disease (ASCVD) remains the number one killer in the western world. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and ezetimibe has been shown to reduce the risk of cardiovascular events. Now, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mabs) are available for high-risk individuals with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy but requiring greater LDL-C reduction. PCSK9 mab outcome trial results from the Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk (FOURIER) study, which was presented at the American College of Cardiology in March 2017, which demonstrated a decrease of 15% in primary and 20% secondary end points over a 2-year period [1••]...
August 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28446516/access-to-non-statin-lipid-lowering-therapies-in-patients-at-high-risk-of-atherosclerotic-cardiovascular-disease
#2
Joshua W Knowles, William B Howard, Lala Karayan, Seth J Baum, Katherine A Wilemon, Christie M Ballantyne, Kelly D Myers
High-intensity statins are recommended for all patients with familial hypercholesterolemia (FH) and non-statin lipid lowering therapies (LLTs) are indicated when there is an inadequate response to statins(1, 2) In the pre-PCSK9 inhibitor (PCSK9i) era only about 40% of FH patients achieved an LDL-C level <100.(3) Partly based on the need for additional therapeutic options in high-risk FH patients, PCSK9 inhibitors were approved for treatment of heterozygous and homozygous FH in 2015. Nevertheless, emerging anecdotal data suggest that access to non-statin LLTs has been a challenge for FH patients though this has not been systematically evaluated...
April 26, 2017: Circulation
https://www.readbyqxmd.com/read/28353527/baclofen-pumps-uses-and-complications
#3
Seth M Woolf, Carl R Baum
Intrathecal baclofen therapy, given via an implanted pump in the abdominal wall either as a continuous infusion or bolus dosing, has been used for more than 25 years to treat the spasticity and dystonia associated with various brain and spinal cord conditions. Pediatric clinicians occasionally encounter baclofen pumps, and in the pediatric setting, significant morbidity can arise from their use. This article presents the background, mechanism of action, uses, and complications of intrathecal baclofen therapy and discusses various management strategies should complications occur...
April 2017: Pediatric Emergency Care
https://www.readbyqxmd.com/read/28328015/pcsk9-inhibitor-access-barriers-issues-and-recommendations-improving-the-access-process-for-patients-clinicians-and-payers
#4
REVIEW
Seth J Baum, Peter P Toth, James A Underberg, Paul Jellinger, Joyce Ross, Katherine Wilemon
The proprotein convertase subtilisin/kexin type 9 inhibitors or monoclonal antibodies likely represent the greatest advance in lipid management in 30 years. In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high-risk patients with familial hypercholesterolemia (FH) and clinical atherosclerotic cardiovascular disease requiring additional lowering of low-density lipoprotein cholesterol. Though many lipid specialists, cardiovascular disease prevention experts, endocrinologists, and others prescribed the drugs on label, they found their directives denied 80% to 90% of the time...
April 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/27783842/the-american-society-for-preventive-cardiology-our-30-year-legacy
#5
Nathan D Wong, Laurence S Sperling, Seth J Baum
No abstract text is available yet for this article.
November 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/27678440/us-physician-practices-for-diagnosing-familial-hypercholesterolemia-data-from-the-cascade-fh-registry
#6
Zahid S Ahmad, Rolf L Andersen, Lars H Andersen, Emily C O'Brien, Iris Kindt, Peter Shrader, Chandna Vasandani, Connie B Newman, Emil M deGoma, Seth J Baum, Linda C Hemphill, Lisa C Hudgins, Catherine D Ahmed, Iftikhar J Kullo, Samuel S Gidding, Danielle Duffy, William Neal, Katherine Wilemon, Matthew T Roe, Daniel J Rader, Christie M Ballantyne, MacRae F Linton, P Barton Duell, Michael D Shapiro, Patrick M Moriarty, Joshua W Knowles
BACKGROUND: In the US familial hypercholesterolemia (FH), patients are underidentified, despite an estimated prevalence of 1:200 to 1:500. Criteria to identify FH patients include Simon Broome, Dutch Lipid Clinic Network (DLCN), or Make Early Diagnosis to Prevent Early Deaths (MEDPED). The use of these criteria in US clinical practices remains unclear. OBJECTIVE: To characterize the FH diagnostic criteria applied by US lipid specialists participating in the FH Foundation's CASCADE FH (CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia) patient registry...
September 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27667377/emerging-treatments-for-heterozygous-and-homozygous-familial-hypercholesterolemia
#7
REVIEW
Seth J Baum, Daniel Soffer, P Barton Duell
Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder marked by extremely high low-density lipoprotein (LDL) cholesterol levels and concomitant premature vascular disease. FH is caused by mutations that most commonly affect three genes integrally involved in the LDL receptor's ability to clear LDL particles from the circulation. Primary intervention efforts to lower LDL cholesterol have centered on therapies that upregulate the LDL receptor. Unfortunately, most patients are insufficiently responsive to traditional LDL-lowering medications...
2016: Reviews in Cardiovascular Medicine
https://www.readbyqxmd.com/read/27462479/focal-correction-of-severe-fixed-kyphosis-with-single-level-posterior-ponte-osteotomy-and-interbody-fusion
#8
Seth S Molloy, Faiz U Ahmad, Griffin R Baum, Barth A Green, Nathan H Lebwohl
OBJECTIVE: To report the successful correction of a severe, fixed kyphotic deformity utilizing a combination posterior lumbar interbody fusion (PLIF) and Ponte osteotomy at the site of acute kyphosis. SUMMARY OF BACKGROUND DATA: There have been no reports on the experience and surgical strategy of combined one-level focal PLIF and Ponte osteotomy for fixed severe kyphotic deformity. Typically, these corrections would need a pedicle subtraction osteotomy or a vertebrectomy...
2016: Curēus
https://www.readbyqxmd.com/read/27422124/focus-on-pcsk9-inhibitors-from-genetics-to-clinical-practice
#9
Marc S Sabatine, James A Underberg, Michael Koren, Seth J Baum
Elevation of low-density lipoprotein cholesterol (LDL-C) is an important cause of atherosclerotic cardiovascular disease (ASCVD). Over the years, clinical outcome studies with LDL-C lowering agents have revealed that reducing LCL-C levels is effective in reducing rates of major ASCVD events. Although secondary factors play a role in clinical expression, severe lipid disorders often have a strong genetic component. Genetic revelations have provided novel targets for improving LDL-C management in high-risk individuals...
October 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27246162/defining-severe-familial-hypercholesterolaemia-and-the-implications-for-clinical-management-a-consensus-statement-from-the-international-atherosclerosis-society-severe-familial-hypercholesterolemia-panel
#10
REVIEW
Raul D Santos, Samuel S Gidding, Robert A Hegele, Marina A Cuchel, Philip J Barter, Gerald F Watts, Seth J Baum, Alberico L Catapano, M John Chapman, Joep C Defesche, Emanuela Folco, Tomas Freiberger, Jacques Genest, G Kees Hovingh, Mariko Harada-Shiba, Steve E Humphries, Ann S Jackson, Pedro Mata, Patrick M Moriarty, Frederick J Raal, Khalid Al-Rasadi, Kausik K Ray, Zelijko Reiner, Eric J G Sijbrands, Shizuya Yamashita
Familial hypercholesterolaemia is common in individuals who had a myocardial infarction at a young age. As many as one in 200 people could have heterozygous familial hypercholesterolaemia, and up to one in 300 000 individuals could be homozygous. The phenotypes of heterozygous and homozygous familial hypercholesterolaemia overlap considerably; the response to treatment is also heterogeneous. In this Review, we aim to define a phenotype for severe familial hypercholesterolaemia and identify people at highest risk for cardiovascular disease, based on the concentration of LDL cholesterol in blood and individuals' responsiveness to conventional lipid-lowering treatment...
October 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27055975/accelerated-atherosclerosis-and-elevated-lipoprotein-a-after-liver-transplantation
#11
Abdulla A Damluji, Diala El-Maouche, Ali Alsulaimi, Paul Martin, Robert D Shamburek, Ronald B Goldberg, Seth J Baum, Eduardo J de Marchena
Cumulative evidence suggests that lipoprotein(a) [Lp(a)] exerts an independent effect on the initiation and progression of atherosclerotic cardiovascular disease. The genetically mediated expression of apolipoprotein(a), which is the key structural and functional component of Lp(a), occurs in hepatocytes with subsequent extracellular Lp(a) assembly at the hepatic cell surface. Here, we describe a case of elevated Lp(a) concentrations identified after (and likely acquired by) orthotopic liver transplantation that contributed to accelerated atherosclerotic cardiovascular disease despite intensive therapeutic interventions...
March 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27013694/treatment-gaps-in-adults-with-heterozygous-familial-hypercholesterolemia-in-the-united-states-data-from-the-cascade-fh-registry
#12
Emil M deGoma, Zahid S Ahmad, Emily C O'Brien, Iris Kindt, Peter Shrader, Connie B Newman, Yashashwi Pokharel, Seth J Baum, Linda C Hemphill, Lisa C Hudgins, Catherine D Ahmed, Samuel S Gidding, Danielle Duffy, William Neal, Katherine Wilemon, Matthew T Roe, Daniel J Rader, Christie M Ballantyne, MacRae F Linton, P Barton Duell, Michael D Shapiro, Patrick M Moriarty, Joshua W Knowles
BACKGROUND: Cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the United States remain poorly described. In 2013, the FH Foundation launched the Cascade Screening for Awareness and Detection (CASCADE) of FH Registry to address this knowledge gap. METHODS AND RESULTS: We conducted a cross-sectional analysis of 1295 adults with heterozygous FH enrolled in the CASCADE-FH Registry from 11 US lipid clinics...
June 2016: Circulation. Cardiovascular Genetics
https://www.readbyqxmd.com/read/26892999/statins-and-diabetes
#13
REVIEW
Kevin C Maki, Mary R Dicklin, Seth J Baum
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes. The NLA panel advocated following the standards of care from the American Diabetes Association for screening and diagnosis of diabetes, and emphasized the importance of lifestyle modification...
March 2016: Endocrinology and Metabolism Clinics of North America
https://www.readbyqxmd.com/read/26337173/insights-into-statin-intolerance
#14
Stephen Kopecky, Seth Baum, JoAnne M Foody, Michael Koren, James McKenney, Laurence Sperling, Nathan D Wong
No abstract text is available yet for this article.
September 2015: Clinical Cardiology
https://www.readbyqxmd.com/read/25939296/statins-and-diabetes
#15
REVIEW
Kevin C Maki, Mary R Dicklin, Seth J Baum
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes. The NLA panel advocated following the standards of care from the American Diabetes Association for screening and diagnosis of diabetes, and emphasized the importance of lifestyle modification...
May 2015: Cardiology Clinics
https://www.readbyqxmd.com/read/25499935/the-doctor-s-dilemma-challenges-in-the-diagnosis-and-care-of-homozygous-familial-hypercholesterolemia
#16
EDITORIAL
Seth J Baum, E J G Sijbrands, Pedro Mata, Gerald F Watts
No abstract text is available yet for this article.
November 2014: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/24142523/adherence-to-preventive-exercises-and-self-reported-swallowing-outcomes-in-post-radiation-head-and-neck-cancer-patients
#17
Eileen Huh Shinn, Karen Basen-Engquist, George Baum, Sven Steen, Rachel Freeman Bauman, William Morrison, Adam Seth Garden, Cathleen Sheil, Kelly Kilgore, Katherine A Hutcheson, Denise Barringer, Ying Yuan, Jan S Lewin
BACKGROUND: To reduce the risk of long-term swallowing complications after radiation, swallowing exercises may be helpful. Both the rate of adherence to swallowing exercises and its impact on future swallowing function are unknown. METHODS: In all, 109 patients with oropharyngeal cancer beginning radiation were tracked for 2 years to determine adherence to swallowing exercises. Participants completed the MD Anderson Dysphagia Inventory (MDADI) 1-2 years after treatment, to assess self-reported swallowing function...
December 2013: Head & Neck
https://www.readbyqxmd.com/read/23102543/a-survey-of-internists-and-cardiologists-are-discoveries-in-fatty-acids-truly-being-translated-into-clinical-practice
#18
Seth J Baum
No abstract text is available yet for this article.
January 2013: Prostaglandins, Leukotrienes, and Essential Fatty Acids
https://www.readbyqxmd.com/read/22658146/fatty-acids-in-cardiovascular-health-and-disease-a-comprehensive-update
#19
REVIEW
Seth J Baum, Penny M Kris-Etherton, Walter C Willett, Alice H Lichtenstein, Lawrence L Rudel, Kevin C Maki, Jay Whelan, Christopher E Ramsden, Robert C Block
Research dating back to the 1950s reported an association between the consumption of saturated fatty acids (SFAs) and risk of coronary heart disease. Recent epidemiological evidence, however, challenges these findings. It is well accepted that the consumption of SFAs increases low-density lipoprotein cholesterol (LDL-C), whereas carbohydrates, monounsaturated fatty acids (MUFAs), and polyunsaturated fatty acids (PUFAs) do not. High-density lipoprotein (HDL)-C increases with SFA intake. Among individuals who are insulin resistant, a low-fat, high-carbohydrate diet typically has an adverse effect on lipid profiles (in addition to decreasing HDL-C, it also increases triglyceride and LDL particle concentrations)...
May 2012: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/22528120/evidence-based-medicine-what-s-the-evidence
#20
EDITORIAL
Seth J Baum
No abstract text is available yet for this article.
May 2012: Clinical Cardiology
keyword
keyword
95648
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"